Chemotherapy tips the scale in favour of cancer-fighting B cells

Ke Rui¹, Fan Xiao^{2

3}, Jie Tian¹, Jixiang Chen⁴, Liwei Lu^{2

3}

Affiliations

¹ Department of Laboratory Medicine, Institute of Medical Immunology of Jiangsu University, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
² Department of Pathology and Shenzhen Institute of Research and Innovation, The University of Hong Kong, Hong Kong, China.
³ Centre for Oncology and Immunology, Hong Kong Science Park, Hong Kong, China.
⁴ Department of Gastrointestinal Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, China.

Comment

Ke Rui et al. Clin Transl Med. 2023 Sep.

. 2023 Sep;13(9):e1407.

doi: 10.1002/ctm2.1407.

Ke Rui¹, Fan Xiao^{2

3}, Jie Tian¹, Jixiang Chen⁴, Liwei Lu^{2

3}

¹ Department of Laboratory Medicine, Institute of Medical Immunology of Jiangsu University, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
² Department of Pathology and Shenzhen Institute of Research and Innovation, The University of Hong Kong, Hong Kong, China.
³ Centre for Oncology and Immunology, Hong Kong Science Park, Hong Kong, China.
⁴ Department of Gastrointestinal Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, China.

No abstract available

Conflict of interest statement

The authors declare they have no conflicts of interest.

The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment.
Lv J, Wei Y, Yin JH, Chen YP, Zhou GQ, Wei C, Liang XY, Zhang Y, Zhang CJ, He SW, He QM, Huang ZL, Guan JL, Shen JY, Li XM, Li JY, Li WF, Tang LL, Mao YP, Guo R, Sun R, Zheng YH, Zhou WW, Xiong KX, Wang SQ, Jin X, Liu N, Li GB, Kuang DM, Sun Y, Ma J. Lv J, et al. Nat Med. 2023 Jun;29(6):1424-1436. doi: 10.1038/s41591-023-02369-6. Epub 2023 Jun 6. Nat Med. 2023. PMID: 37280275

1. Lv J, Wei Y, Yin J‐H, et al. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat Med. 2023;29:1424‐1436. doi: 10.1038/s41591-023-02369-6 - DOI - PubMed
1. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28:690‐714. doi: 10.1016/j.ccell.2015.10.012 - DOI - PubMed
1. Wu YC, Yang S, Ma J, et al. Spatiotemporal immune landscape of colorectal cancer liver metastasis at single‐cell level. Cancer Discov. 2022;12:134‐153. doi: 10.1158/2159-8290.Cd-21-0316 - DOI - PubMed
1. Hong S, Zhang Z, Liu H, et al. B cells are the dominant antigen‐presenting cells that activate naive CD4(+) T cells upon immunization with a virus‐derived nanoparticle antigen. Immunity. 2018;49:695‐708.e4. doi: 10.1016/j.immuni.2018.08.012 - DOI - PubMed
1. Cui C, Wang J, Fagerberg E, et al. Neoantigen‐driven B cell and CD4 T follicular helper cell collaboration promotes anti‐tumor CD8 T cell responses. Cell. 2021;184:6101‐6118.e13. doi: 10.1016/j.cell.2021.11.007 - DOI - PMC - PubMed